-
★
Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26,
(Hinzugefügt: 25.10.2022 um 13:30 Uhr)
https://www.cdc.gov/mmwr/volumes/71/wr/mm7142a3.htm
-
★
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
(Hinzugefügt: 26.04.2022 um 13:03 Uhr)
https://www.nejm.org/doi/10.1056/NEJMoa2119451
-
★
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
(Hinzugefügt: 03.04.2022 um 17:05 Uhr)
https://www.science.org/doi/10.1126/scitranslmed.abm2311
-
★
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
(Hinzugefügt: 21.12.2021 um 12:37 Uhr)
https://www.cell.com/med/fulltext/S2666-6340(21)00382-2
-
★
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
(Hinzugefügt: 18.12.2021 um 14:56 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2115463
-
★
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
(Hinzugefügt: 06.12.2021 um 13:37 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02717-3/fulltext
-
★
SARS-CoV-2: Schutzwirkung von BNT162b2 lässt etwas schneller nach als bei mRNA-1273
(Hinzugefügt: 30.10.2021 um 14:57 Uhr)
https://www.aerzteblatt.de/nachrichten/127433/SARS-CoV-2-Schutzwirkung-von-BNT162b2-laesst-etwas-schneller-nach-als-bei-mRNA-1273
-
Susceptibility to SARS-CoV-2 Omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination
(Hinzugefügt: 26.10.2022 um 14:06 Uhr)
https://www.cell.com/iscience/fulltext/S2589-0042(22)01651-0
-
Immune memory to SARS-CoV-2 Omicron BA.1 breakthrough infections: To change the vaccine or not?
(Hinzugefügt: 06.06.2022 um 08:53 Uhr)
https://www.science.org/doi/10.1126/sciimmunol.abq5901
-
Humoral and cellular immune memory to four COVID-19 vaccines
(Hinzugefügt: 30.05.2022 um 13:53 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(22)00653-5
-
Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
(Hinzugefügt: 27.05.2022 um 07:54 Uhr)
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003991
-
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised tr
(Hinzugefügt: 13.05.2022 um 07:35 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00271-7/fulltext
-
SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
(Hinzugefügt: 09.05.2022 um 09:00 Uhr)
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.18.2200178
-
Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
(Hinzugefügt: 09.05.2022 um 08:50 Uhr)
https://www.nature.com/articles/s41467-022-30059-3
-
Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 Infection and Severe Disease in Singapore
(Hinzugefügt: 01.05.2022 um 09:52 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac288/6567428
-
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
(Hinzugefügt: 26.04.2022 um 12:07 Uhr)
https://www.journalofinfection.com/article/S0163-4453(22)00200-6/fulltext
-
Vaccine effectiveness against infection and COVID-19-associated hospitalisation with the Omicron (B.1.1.529) variant after vaccination with the BNT162b2 or mRNA-1273 vaccine: A nationwide Danish cohort study
(Hinzugefügt: 08.04.2022 um 17:25 Uhr)
https://www.researchsquare.com/article/rs-1486018/v1
-
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
(Hinzugefügt: 03.04.2022 um 17:41 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00140-2/fulltext#%20
-
Evaluating COVID-19 vaccines in the real world
(Hinzugefügt: 22.03.2022 um 12:09 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00194-5/fulltext
-
Humoral and cellular immune memory to four COVID-19 vaccines
(Hinzugefügt: 22.03.2022 um 11:32 Uhr)
https://www.biorxiv.org/content/10.1101/2022.03.18.484953v1
-
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
(Hinzugefügt: 22.03.2022 um 11:29 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00129-3/fulltext
-
Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
(Hinzugefügt: 16.03.2022 um 13:58 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00011-3/fulltext
-
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
(Hinzugefügt: 06.03.2022 um 18:37 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2119451
-
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
(Hinzugefügt: 17.02.2022 um 06:45 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2119236
-
mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants
(Hinzugefügt: 17.02.2022 um 05:43 Uhr)
https://www.nature.com/articles/s41598-022-06629-2
-
Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period
(Hinzugefügt: 24.01.2022 um 19:29 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2788408
-
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
(Hinzugefügt: 13.01.2022 um 11:04 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2115481
-
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
(Hinzugefügt: 13.01.2022 um 11:04 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2115463
-
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina
(Hinzugefügt: 13.01.2022 um 11:04 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2117128
-
Covid-19 Vaccine Effectiveness in New York State
(Hinzugefügt: 13.01.2022 um 11:03 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2116063
-
Neue Daten aus GroßbritannienBis zu 80 Prozent Schutz: Das ist die beste Booster-Kombination gegen Omikron
(Hinzugefügt: 31.12.2021 um 09:14 Uhr)
https://www.focus.de/gesundheit/news/bis-zu-80-prozent-schutz-das-ist-die-beste-booster-kombination-gegen-omikron_id_32402961.html
-
Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study
(Hinzugefügt: 23.12.2021 um 20:06 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v2
-
Aufwändige Studie Eine Booster-Kombination enttäuscht
(Hinzugefügt: 09.12.2021 um 17:55 Uhr)
https://www.n-tv.de/wissen/Eine-Booster-Kombination-enttaeuscht-article22981694.html
-
Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants
(Hinzugefügt: 09.12.2021 um 16:48 Uhr)
https://wwwnc.cdc.gov/eid/article/28/2/21-1789_article
-
Covid-19 Vaccine Effectiveness in New York State
(Hinzugefügt: 07.12.2021 um 19:29 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2116063?query=featured_coronavirus
-
SARS-CoV-2: Heterologe Impfung führt zu höheren Antikörpertitern
(Hinzugefügt: 07.12.2021 um 17:00 Uhr)
https://www.aerzteblatt.de/nachrichten/129846/SARS-CoV-2-Heterologe-Impfung-fuehrt-zu-hoeheren-Antikoerpertitern
-
Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine
(Hinzugefügt: 06.12.2021 um 13:16 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.03.21267281v1
-
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
(Hinzugefügt: 06.12.2021 um 13:14 Uhr)
https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00604-2/fulltext
-
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
(Hinzugefügt: 04.12.2021 um 09:13 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2115463
-
Covid-19 Vaccine Effectiveness in New York State
(Hinzugefügt: 02.12.2021 um 06:54 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2116063
-
Direct Comparison of Antibody Responses to Four SARS-CoV-2 Vaccines in Mongolia
(Hinzugefügt: 19.11.2021 um 15:52 Uhr)
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(21)00510-2#relatedArticles
-
Monitoring reports of the effectiveness of COVID-19 vaccination
(Hinzugefügt: 19.11.2021 um 15:48 Uhr)
https://www.gov.uk/guidance/monitoring-reports-of-the-effectiveness-of-covid-19-vaccination
-
Pfizer-BioNTech vaccination with Moderna booster jab has ‘slight edge’ in reducing COVID-19 infection risk: Ong Ye Kung
(Hinzugefügt: 19.11.2021 um 15:14 Uhr)
https://www.channelnewsasia.com/singapore/covid-19-vaccine-pfizer-biontech-moderna-booster-which-better-2314886
-
Covid-19 Vaccine Effectiveness Assessment in Chile
(Hinzugefügt: 15.11.2021 um 07:28 Uhr)
https://cdn.who.int/media/docs/default-source/blue-print/chile_rafael-araos_who-vr-call_25oct2021.pdf
-
Protection offered by mRNA-1273 versus BNT162b2 vaccines against SARS-CoV-2 infection and severe COVID-19 in Qatar
(Hinzugefügt: 14.11.2021 um 15:04 Uhr)
https://www.medrxiv.org/content/10.1101/2021.11.12.21266250v1
-
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
(Hinzugefügt: 05.11.2021 um 07:30 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2786039
-
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
(Hinzugefügt: 05.11.2021 um 07:27 Uhr)
https://www.science.org/doi/10.1126/science.abm0620
-
Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity
(Hinzugefügt: 04.11.2021 um 09:19 Uhr)
https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html
-
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
(Hinzugefügt: 04.11.2021 um 08:36 Uhr)
https://www.nature.com/articles/s41591-021-01583-4.epdf?sharing_token=q1cOGqPYORJO60wUuHZ90NRgN0jAjWel9jnR3ZoTv0P9bgT8Qujztqfg4aZUxN-Gizow6Ulnu79bnNk_xrEWiqK78vZEUiKaq-tuoBgfUtbeXyWIlY5qhgYNYuljhEkv9X4twyN7JGtOTniGnR76k1_tkLB4GL-tn2mbaEKntdI%3D
-
Is Moderna Really Better Than Pfizer—Or Is It Just a Higher Dose?
(Hinzugefügt: 01.11.2021 um 09:50 Uhr)
https://www.theatlantic.com/health/archive/2021/10/pfizer-moderna-dose-which-vaccine-best/620501/
-
SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA- versus vector-based vaccination in the general Dutch population
(Hinzugefügt: 29.10.2021 um 13:38 Uhr)
https://www.medrxiv.org/content/10.1101/2021.10.25.21265467v1
-
Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
(Hinzugefügt: 25.10.2021 um 07:27 Uhr)
https://www.mdpi.com/2076-393X/9/11/1223
-
https://www.nejm.org/doi/full/10.1056/NEJMc2113864
(Hinzugefügt: 22.10.2021 um 16:17 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2113864
-
Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study using OpenSAFELY
(Hinzugefügt: 20.10.2021 um 14:35 Uhr)
https://www.medrxiv.org/content/10.1101/2021.10.13.21264937v1
-
Long-term predictions of humoral immunity after two doses of BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
(Hinzugefügt: 20.10.2021 um 14:30 Uhr)
https://www.medrxiv.org/content/10.1101/2021.10.13.21264957v1
-
Time-varying effectiveness of the mRNA-1273, BNT162b2 and Ad26.COV2.S vaccines against SARS-CoV-2 infections and COVID-19 hospitalizations and deaths: an analysis based on observational data from Puerto Rico
(Hinzugefügt: 20.10.2021 um 14:15 Uhr)
https://www.medrxiv.org/content/10.1101/2021.10.17.21265101v1